DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

Discover how lightweight, stateless Thin Clients with read-only OS architectures support compliance, extend hardware lifespan ...

Flood of unreality is an endpoint of algorithm-driven internet and product of an economy dependent on a few top tech firms ...

BIDMC investigator Mary Bouxsein helped secure FDA approval of bone density imaging as a faster endpoint for osteoporosis ...

AstraZeneca’s combination therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC) has failed to meet ...

The latest update is out from VistaGen Therapeutics ( (VTGN) ).

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

Investing.com -- AstraZeneca PLC (ST:AZN) announced Monday that its LATIFY Phase III trial of ceralasertib in combination ...

Despite the disappointing primary results, Biohaven noted some positive trends in specific subgroups, particularly among patients with more severe depression at screening and baseline. The company ...

Explore the top antivirus solutions for Windows in 2025, focusing on comprehensive security, compliance, and resilience for enterprises in the evolving threat landscape.

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...